Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
8.60
-0.93 (-9.76%)
At close: Apr 28, 2026, 4:00 PM EDT
8.70
+0.10 (1.22%)
After-hours: Apr 28, 2026, 7:35 PM EDT
Immix Biopharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Immix Biopharma stock have an average target of 19.2, with a low estimate of 15 and a high estimate of 23. The average target predicts an increase of 123.26% from the current stock price of 8.60.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 30, 2026.
Analyst Ratings
The average analyst rating for Immix Biopharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 1 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +74.42% | Mar 30, 2026 |
| Mizuho | Mizuho | Buy Maintains $14 → $15 | Buy | Maintains | $14 → $15 | +74.42% | Mar 30, 2026 |
| Citizens | Citizens | Buy Reiterates $23 | Buy | Reiterates | $23 | +167.44% | Mar 27, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $15 | Strong Buy | Maintains | $12 → $15 | +74.42% | Mar 27, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $20 | Buy | Initiates | $20 | +132.56% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
57.54M
EPS This Year
-0.79
from -0.89
EPS Next Year
-0.74
from -0.79
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 98.6M | ||||||
| Avg | n/a | 57.5M | ||||||
| Low | n/a | 17.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.56 | -0.07 | ||||||
| Avg | -0.79 | -0.74 | ||||||
| Low | -0.94 | -1.45 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.